New BIOSECURE bill “reinforces the national security imperative of the biotechnology industry”

May 9, 2024

Biotechnology Innovation Organization (BIO) logo

House lawmakers today unveiled a new draft of the BIOSECURE Act. Shortly after, BIO President and CEO, John F. Crowley, made the following statement:

“The BIOSECURE bill released in the House today reinforces the national security imperative of the biotechnology industry as a critical strategic asset of the United States of America. It highlights a key vulnerability in our global supply chain and importantly provides a reasonable timeframe for companies to decouple their reliance on China-based biomanufacturing. It ensures during this transition that important biomedical research will not be slowed and that patients will have unimpeded access to life saving medicines.

“BIO applauds this work and supports this BIOSECURE legislation. On behalf of our member companies and the patients we represent and serve, BIO thanks the bill sponsors and the Committees for taking into consideration the findings of our recently released survey on key elements of the global supply chain.

“We will continue work with lawmakers on future policies that promote the U.S. as the global leader in biotechnology and as the medicine chest of the world. We look forward to advancing the extraordinary and coordinated policies and programs necessary to redomicile all key parts of the global biopharmaceutical supply chain here in the U.S. for the benefit of the American public and for the entire world.”

Georgia Life Sciences Statement on the Most Favored Nation Executive Order

By Maria Thacker Goethe • May 16, 2025
Georgia is home to a dynamic and fast-growing life sciences industry—built on bold ideas, scientific risk-taking, and an unwavering commitment to improving patient outcomes. That progress depends on smart, forward-looking policies that support innovation, investment, and access to care. The Most Favored Nation (MFN) policy outlined in this week’s Executive Order threatens to undermine those goals. By tying U.S. drug reimbursement to artificially low prices set by foreign governments, MFN would effectively import price controls from systems that frequently delay—or outright deny—patient access to new therapies. This policy would have real and damaging consequences: stifling innovation, weakening our national leadership in biomedical R&D, and jeopardizing the survival of early-stage biotech companies that form the backbone of Georgia’s life sciences economy. The cost of these short-sighted policies is not theoretical. It means fewer life-saving therapies making it to market—especially for patients with rare, complex, or life-threatening diseases. Studies have repeatedly shown that countries with strict price controls suffer from slower access to breakthrough treatments, if they receive them at all. Georgia Life Sciences urges the Administration and Congress to reject policies that compromise patient care and biomedical progress. Instead, we must work together on balanced solutions that lower out-of-pocket costs for patients while preserving America’s innovation ecosystem. We remain committed to partnering with policymakers to ensure patients in Georgia—and across the country—continue to benefit from the scientific advances our sector delivers every day.

Georgia Life Sciences Designates Augusta as Newest BioReady® Community

By Sheran Brown • May 15, 2025
Georgia Life Sciences Designates Augusta as Newest BioReady® Community

Georgia Life Sciences Membership Drive 2025

By Sheran Brown • May 14, 2025
Strength in Science. Power in Numbers. In a year filled with political uncertainty, one thing is clear: Georgia’s life sciences industry must speak with a united voice. From federal policy shifts to state-level regulatory changes, the decisions being made are directly impacting funding, innovation pipelines, workforce policy, and healthcare access. If we don’t shape the narrative, someone else will. That’s why now is the time to join Georgia Life Sciences . Why Join Now? Policy Advocacy : Amplify your voice where it matters—at the Capitol and in Congress. Visibility & Influence: Be recognized as part of Georgia’s innovation backbone. Networking & Growth : Tap into a thriving ecosystem of researchers, entrepreneurs, investors, and executives. Collective Impact: The greater our numbers, the stronger our position. The Stakes Are High As political tides shift, science needs champions—not just in the lab, but at the table where decisions are made. Your membership isn’t just a badge—it’s a signal that science will not sit on the sidelines. Join Today. Lead Tomorrow. Membership applications received by June 30 qualify for a 50% discount on first year dues . Applies to new memberships only.
MORE POSTS